Bcl-2 hijacks the arsenic trioxide resistance in SH-SY5Y cells
(2022) In Journal of Cellular and Molecular Medicine 26(2). p.563-569- Abstract
Aresenic trioxide (ATO) is proven to be active against leukaemia cells by inducing apoptosis and differentiation. Even though ATO could effectively induce remissions of leukaemia cells, the drug resistance was observed occasionally. To further dissect the mechanism of ATO resistance, we selected the ATO-resistant SH-SY5Y cells and found that Bcl-2 controlled the sensitivity of ATO in SH-SY5Y cells. We report that necroptosis, autophagy, NF-ƘB and MAPK signalling pathway are not involved in ATO-induced apoptosis. Moreover, the ATO-resistant cells showed distinct mitochondrial morphology compared with that of ATO-sensitive cells. Intriguingly, nude mice-bearing ATO-sensitive cells derived xenograft tumours are more sensitive to ATO... (More)
Aresenic trioxide (ATO) is proven to be active against leukaemia cells by inducing apoptosis and differentiation. Even though ATO could effectively induce remissions of leukaemia cells, the drug resistance was observed occasionally. To further dissect the mechanism of ATO resistance, we selected the ATO-resistant SH-SY5Y cells and found that Bcl-2 controlled the sensitivity of ATO in SH-SY5Y cells. We report that necroptosis, autophagy, NF-ƘB and MAPK signalling pathway are not involved in ATO-induced apoptosis. Moreover, the ATO-resistant cells showed distinct mitochondrial morphology compared with that of ATO-sensitive cells. Intriguingly, nude mice-bearing ATO-sensitive cells derived xenograft tumours are more sensitive to ATO treatment compared with that of ATO-resistant cells. These data demonstrate that cancer cells can acquire the ATO-resistance ability by increasing the Bcl-2 expression.
(Less)
- author
- Wang, Jinling ; Peng, Xiaohui ; Yang, Daowei LU ; Guo, Mengyu ; Xu, Xiao ; Yin, Fengyue ; Wang, Yu ; Huang, Jiaqing ; Zhan, Linghui and Qi, Zhongquan
- organization
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Cellular and Molecular Medicine
- volume
- 26
- issue
- 2
- pages
- 7 pages
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:34910369
- scopus:85121286475
- ISSN
- 1582-1838
- DOI
- 10.1111/jcmm.17128
- language
- English
- LU publication?
- yes
- id
- 45b1850a-9c82-4f51-9954-bdd26865c293
- date added to LUP
- 2022-01-31 14:45:47
- date last changed
- 2025-07-30 03:36:00
@article{45b1850a-9c82-4f51-9954-bdd26865c293,
abstract = {{<p>Aresenic trioxide (ATO) is proven to be active against leukaemia cells by inducing apoptosis and differentiation. Even though ATO could effectively induce remissions of leukaemia cells, the drug resistance was observed occasionally. To further dissect the mechanism of ATO resistance, we selected the ATO-resistant SH-SY5Y cells and found that Bcl-2 controlled the sensitivity of ATO in SH-SY5Y cells. We report that necroptosis, autophagy, NF-ƘB and MAPK signalling pathway are not involved in ATO-induced apoptosis. Moreover, the ATO-resistant cells showed distinct mitochondrial morphology compared with that of ATO-sensitive cells. Intriguingly, nude mice-bearing ATO-sensitive cells derived xenograft tumours are more sensitive to ATO treatment compared with that of ATO-resistant cells. These data demonstrate that cancer cells can acquire the ATO-resistance ability by increasing the Bcl-2 expression.</p>}},
author = {{Wang, Jinling and Peng, Xiaohui and Yang, Daowei and Guo, Mengyu and Xu, Xiao and Yin, Fengyue and Wang, Yu and Huang, Jiaqing and Zhan, Linghui and Qi, Zhongquan}},
issn = {{1582-1838}},
language = {{eng}},
number = {{2}},
pages = {{563--569}},
publisher = {{Wiley-Blackwell}},
series = {{Journal of Cellular and Molecular Medicine}},
title = {{Bcl-2 hijacks the arsenic trioxide resistance in SH-SY5Y cells}},
url = {{http://dx.doi.org/10.1111/jcmm.17128}},
doi = {{10.1111/jcmm.17128}},
volume = {{26}},
year = {{2022}},
}